PetVivo Sets Fiscal First Quarter 2025 Conference Call for Wednesday, August 14 at 5:00 p.m. ET
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company specializing in innovative therapeutic medical devices for equines and companion animals, has announced its upcoming fiscal first quarter 2025 conference call. The call is scheduled for Wednesday, August 14, 2024, at 5:00 p.m. Eastern time. PetVivo management will host the presentation, which will be followed by a question-and-answer session.
Financial results for the quarter ended June 30, 2024, will be released in a press release prior to the call. Interested parties can join the call via a toll-free dial-in number or access the live webcast through the company's website. A replay of the webcast will be available after the conference call.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), una delle principali aziende biomediche specializzate in dispositivi medici terapeutici innovativi per cavalli e animali da compagnia, ha annunciato la sua prossima conference call per il primo trimestre fiscale 2025. La chiamata è programmata per mercoledì 14 agosto 2024, alle 17:00 ora orientale. La direzione di PetVivo ospiterà la presentazione, che sarà seguita da una sessione di domande e risposte.
I risultati finanziari del trimestre conclusosi il 30 giugno 2024 saranno rilasciati tramite un comunicato stampa prima della chiamata. Le parti interessate possono unirsi alla chiamata tramite un numero verde oppure accedere alla diretta web attraverso il sito web dell'azienda. Una registrazione della trasmissione sarà disponibile dopo la conference call.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), una de las principales empresas biomédicas especializadas en dispositivos médicos terapéuticos innovadores para equinos y animales de compañía, ha anunciado su próxima conferencia telefónica para el primer trimestre fiscal de 2025. La llamada está programada para miércoles 14 de agosto de 2024, a las 5:00 p.m. hora del Este. La dirección de PetVivo liderará la presentación, que será seguida de una sesión de preguntas y respuestas.
Los resultados financieros del trimestre que finalizó el 30 de junio de 2024 se publicarán en un comunicado de prensa antes de la llamada. Las partes interesadas pueden unirse a la llamada a través de un número de marcación gratuita o acceder a la transmisión en vivo a través del sitio web de la empresa. Una grabación de la transmisión estará disponible después de la conferencia telefónica.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), 말과 반려동물을 위한 혁신적인 치료 의료 기기에 전문화된 선도적인 생물 의학 회사가 2025 회계년도 1분기 컨퍼런스 콜을 발표했습니다. 이 전화 회의는 2024년 8월 14일 수요일 오후 5시 동부 표준시에 예정되어 있습니다. PetVivo의 경영진이 발표를 주관하며, 이후에는 질문 및 답변 시간이 진행됩니다.
2024년 6월 30일로 종료된 분기의 재무 결과는 전화 회의 전에 보도 자료로 발표될 예정입니다. 관심 있는 분들은 무료 전화 번호로 해당 전화 회의에 접속하시거나 회사 웹사이트를 통해 실시간 웹캐스트에 접속할 수 있습니다. 웹캐스트의 재생은 전화 회의 후에 제공될 것입니다.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), une entreprise biomédicale de premier plan spécialisée dans les dispositifs médicaux thérapeutiques innovants pour les équidés et les animaux de compagnie, a annoncé sa prochaine conférence téléphonique pour le premier trimestre fiscal 2025. La conférence est prévue pour le mercredi 14 août 2024, à 17h00, heure de l'Est. La direction de PetVivo animera la présentation, suivie d'une session de questions et réponses.
Les résultats financiers pour le trimestre qui s'est terminé le 30 juin 2024 seront publiés dans un communiqué de presse avant l'appel. Les parties intéressées peuvent participer à l'appel par un numéro de composition sans frais ou accéder au webinaire en direct via le site internet de l'entreprise. Un enregistrement du webinaire sera disponible après la conférence téléphonique.
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), ein führendes biomedizinisches Unternehmen, das sich auf innovative therapeutische Medizinprodukte für Pferde und Begleittiere spezialisiert hat, hat seine bevorstehende Telefonkonferenz für das erste Quartal des Geschäftsjahres 2025 angekündigt. Der Anruf ist für Mittwoch, den 14. August 2024, um 17:00 Uhr Eastern Time geplant. Das Management von PetVivo wird die Präsentation leiten, die von einer Fragerunde gefolgt wird.
Die finanziellen Ergebnisse für das zum 30. Juni 2024 abgeschlossene Quartal werden in einer Pressemitteilung vor dem Anruf veröffentlicht. Interessierte können über eine gebührenfreie Telefonnummer an dem Anruf teilnehmen oder auf die Live-Webcast über die Unternehmenswebsite zugreifen. Eine Aufzeichnung des Webcasts wird nach der Telefonkonferenz verfügbar sein.
- None.
- None.
MINNEAPOLIS, MN, US, Aug. 08, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, will hold a conference call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern time to discuss results for the fiscal first quarter ended June 30, 2024. The financial results will be issued in a press release prior to the call.
PetVivo management will host the presentation, followed by a question-and-answer period.
Date: Wednesday, August 14, 2024
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
Toll-free dial-in number: 1-253-215-8782
Conference ID: 85913290613
Passcode: 187583
Webcast (live and replay): here
A replay of the webcast will be available through the same link following the conference call.
The conference call webcast is also available via a link in the Investors section of the company’s website at petvivo.com/investors.
If you require any assistance connecting to the call, please contact CMA at 1-949-432-7566.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company’s commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Investor Contact
Ronald Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email contact
FAQ
When is PetVivo's (PETV) fiscal Q1 2025 earnings call scheduled?
How can investors access PetVivo's (PETV) Q1 2025 earnings call?
What period does PetVivo's (PETV) upcoming earnings report cover?
Will there be a replay available for PetVivo's (PETV) Q1 2025 earnings call?
